HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study

[1]  H. Kitchener,et al.  Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England , 2010, British Journal of Cancer.

[2]  J. Peto,et al.  Optimal Threshold for a Positive Hybrid Capture 2 Test for Detection of Human Papillomavirus: Data from the ARTISTIC Trial , 2009, Journal of Clinical Microbiology.

[3]  Theresa M. Marteau,et al.  Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study , 2009, BMJ : British Medical Journal.

[4]  J. Little,et al.  Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial , 2009, BMJ : British Medical Journal.

[5]  J. Dillner,et al.  Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate , 2009, Journal of cellular and molecular medicine.

[6]  J. Cuzick,et al.  Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears , 2008, Cancer Epidemiology Biomarkers & Prevention.

[7]  Xavier Castellsagué,et al.  Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.

[8]  J. Peto,et al.  HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial , 2006, British Journal of Cancer.

[9]  Jane Wolstenholme,et al.  Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies , 2006, BMJ : British Medical Journal.

[10]  H. Kitchener,et al.  Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study , 2006, BMJ : British Medical Journal.

[11]  J. Dillner,et al.  Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. , 2005, Gynecologic oncology.

[12]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[13]  Joakim Dillner,et al.  Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. , 2004, Journal of the National Cancer Institute.

[14]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[15]  A. Guyot,et al.  Evaluation of adjunctive HPV testing by Hybrid Capture II® in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy , 2003, BMC infectious diseases.

[16]  G. Rebello,et al.  Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study , 2001, BMJ : British Medical Journal.

[17]  G. Orth,et al.  Human Papillomavirus Testing in Women With Mild Cytologic Atypia , 2000, Obstetrics and gynecology.

[18]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[19]  J. Cuzick,et al.  Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. , 1996, British Journal of Cancer.